4 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 17 Phase 2, 2 Phase 1, 1 Phase 3.
Follow Immunoglobulin A Nephropathy: new trials by email Literature Review of Immunoglobulin A Nephropathy trials Research Report on Immunoglobulin A Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN Iptacopan - Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-21 | 2026-07-29 |
| A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy HS-10390, Irbesartan - Immunoglobulin a Nephropathy | Phase 2 | Not yet recruiting | Hansoh BioMedical R&D Company | 90 | 2024-11-01 | 2024-10-10 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab 400 mg s.c. Q4weeks - Immunoglobulin A Nephropathy | Phase 2 / Phase 3 | Enrolling by invitation | Otsuka Pharmaceutical Development & Commercialization, Inc. | 600 | 2022-04-05 | 2026-05-05 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) ALXN2050, Placebo - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2022-01-14 | 2025-10-15 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo, Background Therapy - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 123 | 2021-01-19 | 2026-01-22 |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy Sparsentan - Immunoglobulin A Nephropathy, Kidney Diseases | Phase 2 | Recruiting | University of Leicester | 24 | 2020-12-10 | 2026-06-03 |
| Safety and Efficacy Study of VIS649 for IgA Nephropathy Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649 - Immunoglobulin A Nephropathy, Glomerular Disease | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 155 | 2020-07-20 | 2026-04-24 |
| Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy SM101, Placebo - Immunoglobulin A Nephropathy | Phase 2 | Withdrawn | Baxalta now part of Shire | 2015-12-31 | 2022-02-07 | |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade CCX168 - Immunoglobulin A Nephropathy | Phase 2 | Completed | Amgen | 7 | 2015-03-27 | 2025-03-13 |
Glomerulonephritis, IGA (17) · Glomerulonephritis (4) · Kidney Diseases (3) · Lupus Nephritis (3) · Autoimmune Diseases (2) · Glomerulonephritis, Membranous (2) · Glomerulosclerosis, Focal Segmental (2) · Immune System Diseases (2) · Nephritis, Hereditary (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranoproliferative (1) · Granulomatosis with Polyangiitis (1) · IgA Vasculitis (1)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Urogenital Diseases (17) · Nephritis (16) · Urologic Diseases (16) · Autoimmune Diseases (15) · Immune System Diseases (15) · Kidney Diseases (14) · Glomerulonephritis (13) · Connective Tissue Diseases (5) · Skin and Connective Tissue Diseases (5) · Lupus Erythematosus, Systemic (3) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (2)
sparsentan (3) · Atrasentan (2) · Irbesartan (1) · avacopan (1) · felzartamab (1) · iptacopan (1) · ravulizumab (1) · rhoA GTP-Binding Protein (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Travere Therapeutics, Inc. (2) · Alpine Immune Sciences, Inc. (1) · Amgen (1) · Baxalta now part of Shire (1) · Beijing Mabworks Biotech Co., Ltd. (1) · BioCryst Pharmaceuticals (1) · Biogen (1) · Hansoh BioMedical R&D Company (1) · University of Leicester (1)
United States (11) · Spain (8) · United Kingdom (8) · Australia (7) · South Korea (7) · Italy (6) · China (4) · Germany (4) · Malaysia (4) · Taiwan (4) · Argentina (3) · Brazil (3) · Canada (3) · France (3) · Hong Kong (3)
Radko Komers, MD, PhD (2) · Asher Schachter, M.D. (1) · Carla M Nester, MD, MSA, FASN (1) · Chee Kay Cheung, MBChB PhD (1)
PMID 38299639, PMID 37528520, PMID 39899371, PMID 40938675, PMID 37254256, PMID 37916620, PMID 38724717, PMID 39455063, PMID 41442197, PMID 41904616, PMID 42275148, PMID 42384439
2014 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1)